MDM2 gene amplification and expression in non-small cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
1997

MDM2 Gene Amplification and Expression in Non-Small Cell Lung Cancer

Sample size: 201 publication Evidence: moderate

Author Information

Author(s): M Higashiyama, O Doi, K Kodama, H Yokouchi, T Kasugai, S Ishiguro, K Takami, T Nakayama, I Nishisho

Primary Institution: Osaka Medical Center for Cancer and Cardiovascular Diseases

Hypothesis

What is the clinicopathological and prognostic value of MDM2 abnormalities in non-small-cell lung cancer?

Conclusion

MDM2 protein expression is a favorable prognostic marker, especially among patients without p53 protein accumulation.

Supporting Evidence

  • MDM2 gene amplification was detected in only 2 (7%) of the 30 tested patients.
  • MDM2 protein was found in 48 (24%) of the 201 patients.
  • MDM2-positive patients tended to have a better prognosis (P = 0.062).
  • Among p53-negative patients, those with positive MDM2 expression showed significantly better prognosis (P = 0.039).

Takeaway

This study found that a protein called MDM2 can help doctors predict how well patients with lung cancer might do, especially if they don't have another protein called p53.

Methodology

MDM2 gene amplification and protein expression were analyzed in surgically resected non-small-cell lung cancer samples using immunohistochemistry and Southern blot analysis.

Limitations

The study had a relatively small sample size for MDM2 gene amplification analysis.

Participant Demographics

Of the 201 patients, 146 were men and 48 were women, aged between 35 and 83 years (mean 63.4 years).

Statistical Information

P-Value

P = 0.039

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication